One of these proteins, BCL6, when mutated, drives the blood cancer known as diffuse large cell B-cell lymphoma. This kind of cancer-driving protein is also referred to as an oncogene. In lymphoma ...

By redirecting an oncogenic protein like BCL6, responsible for cell immortality ... Initial tests of the molecule on diffuse large cell B-cell lymphoma cells in the lab have shown promising ...

ARV-393 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas.

The data suggest that ARV-393, a PROteolysis TArgeting Chimera (PROTAC) designed to degrade the B-cell lymphoma 6 protein (BCL6), may effectively combine with existing lymphoma treatments to ...

B-cell lymphoma is a type of blood cancer that affects the B lymphocytes of the immune system. They usually arise in the lymph nodes or in other lymphoid tissue, such as the spleen, bone marrow ...

ARV-393 is Arvinas' investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein ...

Arvinas to present preclinical data for PROTAC BCL6 degrader & ARV-393 at 2025 AACR annual meeting in Chicago: New Haven, Connecticut Wednesday, April 23, 2025, 18:00 Hrs [IST] Ar ...